Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600320 · ClinicalTrials.gov registry record · NA
Fareon Open Label Device Clinical Trial
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Not yet
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07600320: Clinical Trial NA study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT07600320 is a NA study that has not yet begun recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07600320, a NA study, has not yet begun recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.
Primary Outcome
Device Completion Rate: Proportion of enrolled participants who complete ≥80% of prescribed device sessions over the study period.
Interventions
- DEVICE Fareon device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What is known before NCT07600320 opens enrollment
NCT07600320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Fareon device is the first listed.
NCT07600320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07600320 about?
NCT07600320 is a clinical study titled "Fareon Open Label Device Clinical Trial". The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limit...
What is the current status of trial NCT07600320?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-05-01. Estimated completion is 2027-04-30.
What interventions are being tested in trial NCT07600320?
The interventions under investigation include: Fareon device (DEVICE).
Who is sponsoring clinical trial NCT07600320?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07600320's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI